Cart
sales@molnova.com
SRT3109
CAS No. 1204707-71-0
SRT3109( SRT3109 | SRT-3109 )
Catalog No. M17881 CAS No. 1204707-71-0
SRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 167 | In Stock |
|
| 5MG | 255 | In Stock |
|
| 10MG | 380 | In Stock |
|
| 25MG | 619 | In Stock |
|
| 50MG | 861 | In Stock |
|
| 100MG | 1152 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSRT3109
-
NoteResearch use only, not for human use.
-
Brief DescriptionSRT3109 is a CXCR2 ligand used in the treatment of chemokine mediated diseases and conditions.
-
DescriptionSRT3109 is a CXCR2 ligand. CXCR2 ligands are potent chemoattractants for neutrophils and play a key role in the emigration of neutrophils from the blood to sites of tissue inflammation. Moreover, CXCR2 signaling may also regulate neutrophil mobilization from the bone marrow. Deletion of the chemokine receptor CXCR2 prevents the recruitment of neutrophils into tissues and subsequent development of experimental Lyme arthritis.
-
In VitroSRT3109 (Example 1) is an antagonist of CXCR2, with a pIC50 of 8.2, and used in the research of chemokine mediated diseases.
-
In Vivo——
-
SynonymsSRT3109 | SRT-3109
-
PathwayOthers
-
TargetOther Targets
-
RecptorCXCR2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number1204707-71-0
-
Formula Weight475.53
-
Molecular FormulaC18H23F2N5O4S2
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL; 210.29 mM
-
SMILESC[C@H]([C@H](CO)O)Nc1cc(nc(n1)SCc1c(c(ccc1)F)F)NS(=O)(=O)N1CCC1
-
Chemical NameN-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3R)-3,4-dihydroxybutan-2-yl)amino)pyrimidin-4-yl)azetidine-1-sulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Syk Inhibitor II hyd...
The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus.
-
8-Bromoguanosine
8-Bromoguanosine is a brominated derivative of guanosine. It is activate lymphocytes through an intracellular mechanism to exert immunostimulatory effects.
-
Roemerine
Roemerine is a potential active xanthine oxidase(XOD) inhibitor, XOD is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout.
